Mersana Therapeutics (MRSN) Tops Q4 EPS by 4c

Mersana Therapeutics (NASDAQ: MRSN) reported Q4 EPS of ($0.11), $0.04 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $16.36 million versus the consensus estimate of $7.38 million.

For earnings history and earnings-related data on Mersana Therapeutics (MRSN) click here.

You May Also Be Interested In

• US Eyes 7.5% China Overcapacity Tariffs Before Xi-Trump Talks - Bloomberg
• Citi maintains buy ratings on Argentina power firms amid sector shifts
• XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook